{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:57:42Z","timestamp":1791053862659,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"publisher","award":["U01 AI09503"],"award-info":[{"award-number":["U01 AI09503"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007890","name":"University of North Carolina at Chapel Hill Center","doi-asserted-by":"publisher","award":["P30 AI050410"],"award-info":[{"award-number":["P30 AI050410"]}],"id":[{"id":"10.13039\/100007890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Using an established pharmacokinetic\/pharmacodynamic tissue model of tenofovir disoproxil fumarate\/emtricitabine for HIV pre-exposure prophylaxis (PrEP), we predict that adding a fourth day of dosing to the 3-day IPERGAY on-demand PrEP regimen (currently approved for men\/transgender women who have sex with men) will be efficacious for on-demand dosing in cisgender women.<\/jats:p>","DOI":"10.1093\/infdis\/jiaf459","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:46:10Z","timestamp":1756381570000},"page":"257-260","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing On-Demand Tenofovir Disoproxil Fumarate\/Emtricitabine Dosing in Women for HIV Prevention"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6948-5202","authenticated-orcid":false,"given":"Nathan","family":"Engel","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B","family":"Dumond","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D M","family":"Kashuba","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0291-5111","authenticated-orcid":false,"given":"Mackenzie L","family":"Cottrell","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2026031304515263600_jiaf459-B1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"2026031304515263600_jiaf459-B2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2026031304515263600_jiaf459-B3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031304515263600_jiaf459-B4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"2026031304515263600_jiaf459-B5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/cid\/ciad021","article-title":"Updating the adherence-response for oral emtricitabine\/tenofovir disoproxil fumarate for human immunodeficiency virus pre-exposure prophylaxis among cisgender women","volume":"76","author":"Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031304515263600_jiaf459-B6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2024.0464","article-title":"HIV preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among cisgender women","volume":"331","author":"Marrazzo","year":"2024","journal-title":"JAMA"},{"key":"2026031304515263600_jiaf459-B7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine","volume":"214","author":"Cottrell","year":"2016","journal-title":"J Infect Dis"},{"key":"2026031304515263600_jiaf459-B8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031304515263600_jiaf459-B9","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra1011874","article-title":"Acute HIV-1 infection","volume":"364","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"2026031304515263600_jiaf459-B10","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase i\/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults","volume":"45","author":"Barditch-Crovo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304515263600_jiaf459-B11","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41591-023-02615-x","article-title":"Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women","volume":"29","author":"Zhang","year":"2023","journal-title":"Nat Med"},{"key":"2026031304515263600_jiaf459-B12","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1038\/s41591-023-02564-5","article-title":"Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence","volume":"29","author":"Moore","year":"2023","journal-title":"Nat Med"},{"key":"2026031304515263600_jiaf459-B13","author":"Stansfield"},{"key":"2026031304515263600_jiaf459-B14","doi-asserted-by":"crossref","first-page":"e106196","DOI":"10.1371\/journal.pone.0106196","article-title":"A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"key":"2026031304515263600_jiaf459-B15","author":"US Centers for Disease Control and Prevention"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/257\/64240618\/jiaf459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/257\/64240618\/jiaf459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:52:35Z","timestamp":1773391955000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/2\/257\/8251364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf459","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,9,11]]}}}